Farag Kameel D.'s Form 4 filing
Akari Therapeutics Plc (AKTX) · filed Aug 19, 2026
- Accession no.
- 0001493152-26-039246
- Filed
- Aug 19, 2026, 5:00 PM ET
- Trade date
- Aug 17, 2026
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not checked
This filing lists 1 non-derivative transaction. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Farag Kameel D.CIK 0002093620 | Officer (Interim CFO) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Aug 17, 2026 | American Depositary Shares representing Ordinary Shares | AGrant or awardAcquired | +1,728 | $7.52 | +$12,994.56 | 23,309 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.